Severe COVID-19 is characterized by acute respiratory distress syndrome (ARDS)-like
hyperinflammation and endothelial dysfunction, that can lead to respiratory and multi organ …

Autotaxin (ATX; ENPP2) is a secreted lysophospholipase D catalyzing the extracellular
production of lysophosphatidic acid (LPA), a pleiotropic signaling phospholipid. Genetic and …

Although there is increasing evidence that oxidative stress and inflammation induced by
COVID-19 may contribute to increased risk and severity of thromboses, the underlying …

Understanding Covid‐19 pathophysiology is crucial for a better understanding of the
disease and development of more effective treatments. Alpha‐1‐antitrypsin (A1AT) is a …

Many drugs have been approved for clinical trials for the treatment of COVID-19 disease,
focusing on either antiviral or anti-inflammatory approaches. Combining antiviral and anti …

No definitive treatment for COVID-19 exists although promising results have been reported
with remdesivir and glucocorticoids. Short of a truly effective preventive or curative vaccine …

The pathogenesis of sepsis involves complex interactions and a systemic inflammatory
response leading eventually to multiorgan failure. Autotaxin (ATX, ENPP2) is a secreted …

Abstract Background Coronavirus disease 2019 (COVID-19) is characterized by immune-
mediated lung injury and complex alterations of the immune system, such as lymphopenia …

Autotaxin (ATX) is a secreted glycoprotein, widely present in biological fluids including
blood. ATX catalyzes the hydrolysis of lysophosphatidylcholine (LPC) to lysophosphatidic …

Thrombosis is a hallmark of severe COVID-19. Alpha-1-antitrypsin (AAT), an inflammation-
inducible serpin with anti-inflammatory, tissue protective and anticoagulant properties may …